INTERPROFESSIONAL COLLABORATION WITH IMMUNE CHECKPOINT INHIBITOR THERAPY: THE ROLES OF GASTROENTEROLOGY, ENDOCRINOLOGY AND NEUROLOGY

被引：2
|
作者：
Seery, Virginia [1 ]
机构：
[1] Beth Israel Deaconess Med Ctr, 375 Longwood Ave, Boston, MA 02215 USA
来源：
SEMINARS IN ONCOLOGY NURSING | 2017年 / 33卷 / 04期
关键词：
immunotherapy; immune checkpoint inhibitors; interprofessional collaboration; NIVOLUMAB PLUS IPILIMUMAB; ADVANCED MELANOMA; ADVERSE EVENTS; POOLED ANALYSIS; PHASE-II; SURVIVAL; SAFETY; BLOCKADE; ANTIBODY; PEMBROLIZUMAB;
D O I：
10.1016/j.soncn.2017.08.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OBJECTIVES: To discuss immune checkpoint inhibitor therapy and identify opportunities for interprofessional collaboration in the management of toxicities in the areas of gastroenterology, endocrinology, and neurology. DATA SOURCES: Published research and education articles in oncology, nursing, and various specialties. CONCLUSION: The use of immune checkpoint inhibitors is expanding; timely management of toxicity is critical for positive patient outcomes. There are many opportunities for interprofessional collaboration in the diagnosis and treatment of immune-related adverse events.
引用
收藏
页码：402 / 414
页数：13
相关论文
共 50 条
  • [1] Collaboration Between Rheumatology and Oncology in Immune Checkpoint Inhibitor Therapy
    Kimpel, Donald L.
    Lewis, Janet E.
    Gaughan, Elizabeth
    Grosh, William W.
    Brenin, Christiana
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2743 - +
  • [2] Collaboration Between Rheumatology and Oncology in Immune Checkpoint Inhibitor Therapy Reply
    Suarez-Almazor, Maria E.
    Thompson, John A.
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2744 - +
  • [3] Immune Checkpoint Inhibitor Therapy Toxicities
    Jim, Heather S. L.
    Knoop, Hans
    Dicker, Adam P.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01): : 87 - 87
  • [4] Immune thrombocytopenia after immune checkpoint inhibitor therapy
    Amanam, Idoroenyi
    Gupta, Rohan
    Pullarkat, Vinod
    Mei, Matthew
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (03) : 677 - 681
  • [5] EMERGING COMPLICATION OF IMMUNE CHECKPOINT INHIBITOR THERAPY
    Buntak, Vesna
    Loutoo, Ariane J.
    Joseph, Phillip
    CHEST, 2023, 164 (04) : 3177A - 3177A
  • [6] Tissue biomarkers of immune checkpoint inhibitor therapy
    Davoudi, Fatemeh
    Moradi, Afshin
    Sadeghirad, Habib
    Kulasinghe, Arutha
    IMMUNOLOGY AND CELL BIOLOGY, 2024, 102 (03): : 179 - 193
  • [7] Immune checkpoint inhibitor therapy for hepatocellular carcinoma
    Ramai, Daryl
    Shapiro, Alexandra
    Facciorusso, Antonio
    Bareggi, Claudia
    Gambini, Donatella
    Rijavec, Erika
    Tomasello, Gianluca
    Galassi, Barbara
    Ghidini, Michele
    ANNALS OF GASTROENTEROLOGY, 2022, 35 (06): : 568 - 576
  • [8] Advanced Research on Immune Checkpoint Inhibitor Therapy
    Imai, Hisao
    Kaira, Kyoichi
    Kagamu, Hiroshi
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [9] Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
    Gubbi, Sriram
    Vijayvergia, Namrata
    Yu, Jian Q.
    Klubo-Gwiezdzinska, Joanna
    Koch, Christian A.
    HORMONE AND METABOLIC RESEARCH, 2022, 54 (12) : 795 - 812
  • [10] Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
    Lee, Juwon
    Han, Youngjin
    Wang, Wenyu
    Jo, HyunA
    Kim, Heeyeon
    Kim, Soochi
    Yang, Kyung-Min
    Kim, Seong-Jin
    Dhanasekaran, Danny N.
    Song, Yong Sang
    BIOMOLECULES, 2021, 11 (08)
12345